CA2588953A1 - Ppar active compounds - Google Patents

Ppar active compounds Download PDF

Info

Publication number
CA2588953A1
CA2588953A1 CA002588953A CA2588953A CA2588953A1 CA 2588953 A1 CA2588953 A1 CA 2588953A1 CA 002588953 A CA002588953 A CA 002588953A CA 2588953 A CA2588953 A CA 2588953A CA 2588953 A1 CA2588953 A1 CA 2588953A1
Authority
CA
Canada
Prior art keywords
optionally substituted
disease
substituted lower
group
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002588953A
Other languages
English (en)
French (fr)
Inventor
Jack Lin
Dean R. Artis
Prabha N. Ibrahim
Chao Zhang
Rebecca Zuckerman
Ryan Bremer
Shenghua Shi
Byunghun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexxikon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2588953A1 publication Critical patent/CA2588953A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
CA002588953A 2004-11-30 2005-11-29 Ppar active compounds Abandoned CA2588953A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63174604P 2004-11-30 2004-11-30
US60/631,746 2004-11-30
US71531205P 2005-09-07 2005-09-07
US60/715,312 2005-09-07
PCT/US2005/043271 WO2006060456A2 (en) 2004-11-30 2005-11-29 Indole derivatives for use as ppar ppar active compounds

Publications (1)

Publication Number Publication Date
CA2588953A1 true CA2588953A1 (en) 2006-06-08

Family

ID=36565676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002588953A Abandoned CA2588953A1 (en) 2004-11-30 2005-11-29 Ppar active compounds

Country Status (6)

Country Link
US (1) US7531568B2 (enExample)
EP (1) EP1819673A2 (enExample)
JP (1) JP2008521829A (enExample)
AU (1) AU2005311925A1 (enExample)
CA (1) CA2588953A1 (enExample)
WO (1) WO2006060456A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20120097512A (ko) 2009-11-18 2012-09-04 플렉시콘, 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
KR20120112623A (ko) 2009-12-23 2012-10-11 플렉시콘, 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
CN103201262B (zh) 2010-08-20 2016-06-01 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2631487C2 (ru) 2011-05-17 2017-09-22 Плексксикон Инк. Модуляция киназ и показания к её применению
EP2714680B1 (en) 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
PE20151280A1 (es) 2012-12-21 2015-09-12 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
NZ630875A (en) 2013-03-15 2017-12-22 Plexxikon Inc Heterocyclic compounds and uses thereof
CA2912568A1 (en) 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016044067A1 (en) 2014-09-15 2016-03-24 Plexxikon Inc. Heterocyclic compounds and uses thereof
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA3129180A1 (en) 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP6921846B6 (ja) 2016-03-16 2021-09-15 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節およびその適応症のための化合物および方法
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
KR102615829B1 (ko) 2017-07-25 2023-12-20 플렉시콘 인코퍼레이티드 키나제를 조정하는 화합물의 제제
AU2018348241B2 (en) 2017-10-13 2023-01-12 Opna Bio SA Solid forms of a compound for modulating kinases
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
CA3176237A1 (en) 2020-04-29 2021-11-04 Jack Lin Synthesis of heterocyclic compounds
CN115894330B (zh) * 2022-09-06 2024-12-10 吉林医药学院 一种1-乙酰基-1h-吲哚-3-基乙酸酯衍生物的合成方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482844A (fr) * 1964-12-31 1967-06-02 Merck & Co Inc Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
FR2009259A1 (enExample) 1968-05-24 1970-01-30 Acraf
GB1573212A (en) * 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
DE3246932A1 (de) * 1982-12-16 1984-06-20 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte 5h-pyrimido(5,4-b)indole
US4568649A (en) * 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4626513A (en) * 1983-11-10 1986-12-02 Massachusetts General Hospital Method and apparatus for ligand detection
DE3483099D1 (de) 1984-03-15 1990-10-04 Immunex Corp Test zur sofortigen feststellung von liganden, testsatz und seine herstellung.
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
GB9004301D0 (en) 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5075313A (en) * 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
EP0610793A1 (en) * 1993-02-08 1994-08-17 Takeda Chemical Industries, Ltd. Tetracyclic morpholine derivatives and their use or analgesics
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
DE69434998T2 (de) * 1993-05-27 2008-03-13 Aventis Pharmaceuticals Inc. Topologisch getrennte, kodierende Festphasen-Bibliotheken
US5840485A (en) * 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
GB9416467D0 (en) 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
US5747276A (en) * 1995-09-15 1998-05-05 The Scripps Research Institute Screening methods for the identification of novel antibiotics
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
WO1998039471A1 (en) * 1997-03-07 1998-09-11 Tropix, Inc. Protease inhibtor assay
US6178384B1 (en) * 1997-09-29 2001-01-23 The Trustees Of Columbia University In The City Of New York Method and apparatus for selecting a molecule based on conformational free energy
ATE333275T1 (de) * 1998-02-23 2006-08-15 Univ South Alabama Indole-3-propionsäure, ihre salze und ester als arzneimittel
US6329389B1 (en) * 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
DE19821002A1 (de) * 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
IL145923A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
PT1177187E (pt) * 1999-04-28 2007-09-03 Sanofi Aventis Deutschland Derivados ácidos de di-arilo como ligados do receptor ppar.
ATE316071T1 (de) 1999-09-17 2006-02-15 Kyorin Seiyaku Kk O-anisamid-derivate
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
SI1285908T1 (sl) 2000-05-29 2008-12-31 Kyorin Seiyaku Kk Substituirani fenilpropionski kislinski derivati
MXPA03003021A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
KR101059776B1 (ko) * 2001-06-12 2011-08-26 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
BR0212512A (pt) * 2001-09-14 2004-10-26 Tularik Inc Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta
MXPA04007414A (es) 2002-02-01 2004-10-11 Hoffmann La Roche Indoles sustituidos como agonistas alfa-1.
US6806265B2 (en) * 2002-05-16 2004-10-19 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004007439A1 (ja) 2002-07-10 2004-01-22 Sumitomo Pharmaceuticals Co., Ltd. ビアリール誘導体
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
CA2511214C (en) 2002-12-20 2012-12-18 Tularik, Inc. Asthma and allergic inflammation modulators
WO2004056740A1 (en) 2002-12-20 2004-07-08 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
AU2003303681A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
CA2532403A1 (en) * 2003-07-17 2005-02-03 James Arnold Ppar active compounds
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
CA2541751A1 (en) 2003-10-14 2005-04-28 Eli Lilly And Company Phenoxyether derivatives as ppar modulators
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
RU2240793C1 (ru) 2003-12-02 2004-11-27 Лимонов Виктор Львович Противоопухолевое средство
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
WO2005092131A1 (en) 2004-03-01 2005-10-06 Mirko Uzelac Bipartite butcher's handshalter with couple
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds

Also Published As

Publication number Publication date
US7531568B2 (en) 2009-05-12
US20060116416A1 (en) 2006-06-01
WO2006060456A2 (en) 2006-06-08
EP1819673A2 (en) 2007-08-22
JP2008521829A (ja) 2008-06-26
WO2006060456A3 (en) 2006-09-21
AU2005311925A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
US7531568B2 (en) PPAR active compounds
US20060135540A1 (en) PPAR active compounds
US20080234349A1 (en) PPAR active compounds
CN101304992A (zh) 用作ppar调节剂的1,3-二取代吲哚衍生物
US20080249137A1 (en) PPAR active compounds
US8053463B2 (en) PPAR active compounds
US7572806B2 (en) PPAR active compounds
Spadoni et al. 2-[N-Acylamino (C1− C3) alkyl] indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists
HRP20050108A2 (hr) Indolinfenilsulfonamidni derivati
CN101605775B (zh) 取代的3-苯基-1-(苯基噻吩基)丙-1-酮类以及3-苯基-1-(苯基呋喃基)丙-1-酮类的衍生物、制备以及用途
US20050197382A1 (en) Indolinone combinatorial libraries and related products and methods for the treatment of disease
WO2004092346A2 (en) Small molecule inhibition of a pdz-domain interaction
CN101296892A (zh) Ppar活性化合物
CN115960032A (zh) 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20121129